Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial

Published:2024-07 Issue:7 Volume:9 Page:2037-2046
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Saland Jeffrey M.,Lieske John C.,Groothoff Jaap W.,Frishberg Yaacov,Shasha-Lavsky Hadas,Magen Daniella,Moochhala Shabbir H.,Simkova Eva,Coenen Martin,Hayes Wesley,Hogan Julien,Sellier-Leclerc Anne-Laure,Willey Richard,Gansner John M.,Hulton Sally-Anne

Funder

Alnylam Pharmaceuticals Inc

Publisher

Elsevier BV

Reference19 articles.

1. Primary hyperoxaluria;Cochat;N Engl J Med,2013

2. Improving treatment options for primary hyperoxaluria;Hoppe;Drugs,2022

3. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type;Mandrile;Kidney Int,2014

4. Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1;Fargue;Kidney Int,2009

5. Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice;Hoyer-Kuhn;Clin J Am Soc Nephrol,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP